Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
+$0.06 today
- Market cap
- $184.11M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
Volume 0.40M
Average 0.31M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Whitehawk Therapeutics Inc
NASDAQ:WHWK
Intrinsic Alpha fair value
Locked
Current Price
$3.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -22.3% | +36.1% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -22.3% over three years. Forward estimates point to Revenue at +36.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Immix Biopharma, Inc. NASDAQ:IMMX | $649.96M | $7.84 | Not rated | -10.1 | +66.43% |
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | $2.54 | Not rated | -7.1 | +82.81% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $167.05M | $1.70 | Not rated | -2.1 | +2.26% |
MacroGenics, Inc. NASDAQ:MGNX | $140.14M | $2.20 | Not rated | -3.6 | +39.44% |
Clene Inc. NASDAQ:CLNN | $56.45M | $3.92 | Not rated | -2.1 | -59.54% |
Pliant Therapeutics, Inc. NASDAQ:PLRX | $43.16M | $0.70 | Not rated | -0.6 | -46.02% |
Oncolytics Biotech Inc. NASDAQ:ONCY | $37.13M | $0.37 | Not rated | -4.3 | -51.70% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | $0.18 | Not rated | -1.5 | -40.77% |
Continue the stock analysis
Jump to another research area for this company.